Novo Nordisk A/S Common Stock (NVO)

The board overhaul follows mass resignations triggered by internal disputes over Novo’s direction.

Korro Bio shares drop after KRRO-110 trial in AATD misses protein goals; company cuts 34% of staff and shifts focus to liver-targeted programs.

CEO Albert Bourla told Yahoo Finance that the acquisition of GLP-1 maker Metsera is part of the company's "right to win" in the obesity drug game.

Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership.

The company has launched two programs, MangoRx Direct and PeachesRx Direct, to provide access to Lilly’s Zepbound and Novo’s Wegovy medicines.

Eli Lilly struck a deal with President Donald Trump last week that could send the stock much higher.

INDIANAPOLIS, IN – November 12, 2025 – Eli Lilly and Company (NYSE: LLY) is experiencing a monumental stock breakout today, sending ripples across the global financial markets. The pharmaceutical behemoth, already a dominant force, has seen its valuation surge on the back of sustained exceptional performance, breakthrough drug developments, and a pipeline

Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study.

Eli Lilly to drop CVS Health's drug benefit plan and move to Rightway in 2026 as Novo Nordisk cuts Wegovy prices in India to defend market share.

The biotech start-up's stock had been rising rapidly in 2025.

Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 inching up 0.2% to 6,846.61.

Novo Nordisk shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc.

Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.

New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers and some providers, faced considerable downward pressure. This divergence highlights a sector grappling with a flurry of groundbreaking drug

The final bid, at $10 billion, is expected to wrap up after Nov. 13 with the next shareholders' vote.

Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks.

The companies announced a huge deal that will have implications for investors.

Pharma companies are under pressure to lower prices in the U.S.

The company continues to have a strong growth outlook ahead.

Weight loss drugs generated about $10 billion for Lilly in the most recent quarter.